unknown
Stage
1
Investors
About
AltruBio is a biopharma company developing antibody therapeutics that target a novel regulator of the immune system to selectively remove chronically over-activated T cells implicated in autoimmune and inflammatory diseases. Its pipeline includes programs for acute graft-versus-host disease and ulcerative colitis.
Explore AltruBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.